Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2− Advanced Breast Cancer

Dalal, Anand A.; Gauthier, Geneviève; Gagnon-Sanschagrin, Patrick; Burne, Rebecca; Guérin, Annie; Niravath, Polly; Small, Tania

doi:10.1007/s12325-018-0764-3

Cited by 10 publications

(11 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…And there are 37.7% of patients received OFS combination therapy in the first line while 30.8 and 22.9% in the second and third lines for patients aged ≤50 years. However, among premenopausal women in the US, OFS combination therapy was used as first-line therapy in 15.9% patients, 47.8% in the second line and 27.7% in the third line for patients with HR+HER2-ABC ( 39 ).…”

Section: Discussionmentioning

confidence: 99%

Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China

Ouyang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

BackgroundClinical guidelines generally recommend endocrine therapy (ET) as first-line treatment of hormone receptor-positive advanced breast cancer (HR+ ABC) whereas chemotherapy (CT) should be considered in the presence of life-threatening disease or limited clinical benefit after three sequential ET regimens. However, it is unclear if real-world clinical practice is in accordance with the current guidelines. This study was to present the real-world treatment patterns and ET regimens among HR+ ABC patients in China.MethodsUsing data from the Nation-wide Multicenter Retrospective Clinical Epidemiology Study of Female Advanced Breast Cancer in China (ClinicalTrials.gov identifier: NCT03047889), we investigated the clinicopathological characteristics, clinical profiles, and treatment patterns of HR+ ABC patients from January 2012 to December 2014.ResultsA total of 2,342 patients with HR+ ABC were included in this study. Our findings revealed that, in comparisons with those receiving initial CT (n = 1445), patients initiated ET (n =402) were significantly older, later recurrent after adjuvant treatment, with a lower rate of visceral involvement and a decreasing quantity of metastatic sites. A total of 1,308 patients received palliative ET while only 18.9% patients (n = 247) reached three lines of ET. Among patients completing more than one line of ET, the median treatment duration was 8 months for the first line, 6 months for the second line, and 3 months for the third line for patients receiving ET. In the advanced setting, the choices of palliative ET regimens were diverse, yet aromatase inhibitor (AI) monotherapy was still the overall mainstay of ET; in contrast, patients were less accessible to everolimus plus AI regimen in this population.ConclusionsLess than one quarter of patients initiated palliative ET for HR+ ABC in routine clinical practice. Patients who received multi-lines of ET experienced successive shorter durations following each line of therapy. This real-life data provides a solid overview of ET for HR+ ABC from China, indicating unmet need for treatment options that improve the effectiveness of endocrine therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China

Ouyang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Retrospective studies have documented persistent gaps in guideline‐concordant care in patients treated in real‐world settings in the U.S. and other countries. Up to 40% of premenopausal women with HR+/HER2− mBC are still receiving first‐line treatment with cytotoxic chemotherapy rather than endocrine therapy . A recent retrospective chart review of 652 women treated with palbociclib following FDA approval found that although the median age of patients receiving the drug was similar to that seen in clinical trials, only about 13% were premenopausal .…”

Section: Discussionmentioning

confidence: 99%

Hormone Receptor–Positive/Human Epidermal Growth Receptor 2–Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents

et al. 2020

View full text Add to dashboard Cite

Breast cancer is the most common malignancy in young women worldwide, accounting for an estimated 30% of new cancer diagnoses and 25% of cancer deaths. Approximately two thirds of young women with breast cancer have hormone receptor–positive (HR+)/human epidermal growth receptor 2–negative (HER2−) tumors. Numerous studies, primarily in early‐stage breast cancer, have demonstrated that young age is an independent risk factor for more aggressive disease and worse outcomes. Although more limited data are available regarding outcomes in young patients with advanced disease, these age‐related disparities suggest that breast cancer in premenopausal women has distinct clinicopathologic and molecular features that can impact treatment outcomes. Until recently, limited data were available on the intrinsic molecular subtypes and genetics of young patients with HR+/HER2− metastatic breast cancer (mBC). In this review, we explore insights into the clinical and pathologic features of HR+/HER2− mBC in younger women derived from recent clinical trials of the cyclin‐dependent kinase 4/6 inhibitors palbociclib (PALOMA‐3), ribociclib (MONALEESA‐7), and abemaciclib (MONARCH 2) and the implications of these findings for clinical practice, guideline development, and future research. Implications for Practice This review provides clinicians with an overview of emerging data on the unique clinicopathologic and molecular features of hormone receptor–positive/human epidermal growth receptor 2–negative metastatic breast cancer (mBC) in premenopausal women, summarizes findings from the most recent clinical trials of endocrine‐based treatment in this patient population, and explores the implications of these findings for clinical practice, guideline development, and future research. Improved understanding of the key factors influencing disease course and treatment response in premenopausal patients with mBC may lead to more timely incorporation of evidence‐based treatment approaches, thereby improving patient care and outcomes.

show abstract

“…Patient characteristics were summarized descriptively on the index date (demographics, calendar year of the initiation of the studied line of therapy, reproductive status [identified by a previously published claims-based algorithm], 28 and prior treatment for aBC) and during the baseline period (time from aBC diagnosis to index date, number of prior lines of therapy for aBC, prior use of chemotherapy and radiation therapy, organ-level metastatic sites, and Quan-Charlson Comorbidity Index [CCI] score 33 ).…”

Section: Study Outcomesmentioning

confidence: 99%

Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors

Burne

Balu²,

Guérin

et al. 2021

Journal of Medical Economics

Self Cite

View full text Add to dashboard Cite

This study was sponsored by Novartis Pharmaceuticals Corporation. The study sponsor was involved in several aspects of the research including the study design, the interpretation of data, the writing of the manuscript, and the decision to submit the manuscript for publication. Declaration of Financial/Other InterestsSB, RS, and MLP are employees and stockholders of Novartis Pharmaceuticals Corporation. RB, AG, and RB are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Novartis Pharmaceuticals Corporation.

show abstract

Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2− Advanced Breast Cancer

Abstract: Novartis Pharmaceuticals Corporation.

Cited by 10 publications

References 14 publications

Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China

Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China

Hormone Receptor–Positive/Human Epidermal Growth Receptor 2–Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents

Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors

Contact Info

Product

Resources

About